Objectives: A strategic system for the screening and testing of new antibiotics was created to facilitate the development of antibiotics that are robustly effective against MDR bacteria.
Introduction
The emergence of antibiotic resistance has become a major clinical and public health threat worldwide. 1, 2 According to a recent report from the United Kingdom, if antimicrobial resistance continues to increase, 10 million people will die annually by 2050, a mortality rate greater than that of cancer. 1 Correct use of antibiotics and the development of novel antibiotics are both necessary to overcome this crisis.
Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa have been identified by the WHO as three critical priority pathogens for the research and development of new antibiotics in 2017. 3 Among Enterobacteriaceae, the WHO has reported extremely high resistance rates in Klebsiella pneumoniae and Escherichia coli, 4 which are common causes of hospital and community infections and have similar antibiotic resistance mechanisms. 5 Understanding the effectiveness of antibiotics against specific resistance mechanisms can help in developing antibiotics and using them responsibly. Traditionally, a large number of clinical drug-resistant isolates are collected and used for testing and screening antibiotics before clinical trials begin. 6 However, the resistance mechanisms of clinical isolates are usually complex and not fully characterized. In particular, it is difficult to verify which mechanism plays the major role in conferring drug resistance. Without this information, it is also difficult to modify efficiently the antibiotic candidates to improve their antimicrobial activity. The system developed in the present study provides a platform technology for testing, screening, selecting and evaluating antibiotics using genetically engineered bacterial strains with individual or combined resistance mechanisms that were constructed from the fully susceptible clinical K. pneumoniae NVT1001 isolate. The chromosome-mediated resistance mechanisms that were constructed in this study are decreased antibiotic permeability, generated by deletion of the genes encoding the outer-membrane proteins OmpK35 and/or OmpK36; 7 active antibiotic export, generated by deletion of the ramR regulatory gene, which leads to overexpression of the AcrAB-TolC efflux pump (Supplementary Methods, Tables S1 and S2, available as Supplementary data at JAC Online); [8] [9] [10] [11] and modification of quinolone target sites via gyrA and/or parC mutations. [12] [13] [14] [15] Most plasmid-mediated mechanisms are specific to one kind of antibiotic group, 16 with this study focusing on b-lactams, quinolones, aminoglycosides, tetracyclines and folate pathway inhibitors. Because many kinds of resistance are conferred by combined resistance mechanisms in the clinical setting, mechanisms related to the same antibiotic group were combined. Testing antibiotics against these combined mechanisms can be used to evaluate further their antimicrobial activities.
To our knowledge, no complete system is available for testing antibiotics against specific resistance mechanisms. This study generated genetically engineered strains with clear and simple resistance mechanisms and evaluated their usability via both in vitro and in vivo assays.
Materials and methods

Ethics
All animal studies were conducted in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Research Council. The protocol was approved by the Institutional Animal Care and Use Committee of the National Defense Medical Center (Taiwan).
Bacterial strains and plasmids
K. pneumoniae NVT1001, capsular serotype 1, is an isolate from a liverabscess patient in Taiwan 17 that was fully susceptible to all antibiotics tested, except ampicillin. The NVT1001 strain was used to construct genetically engineered strains with the antibiotic resistance mechanisms that are shown in Table 1 , and the revertants of the NVT1001 mutants constructed in this study are shown in Table S3 .
In-frame deletion mutagenesis
The plasmid pUT-kmy, which consists of an R6K origin of replication, an mobRP4 origin of transfer, and a kanamycin resistance cassette, 18 was ligated with the sacB gene to generate the plasmid pUT-KB, which was then used to construct the mutants. 19 The plasmid pUT-KB is a suicide vector containing the counter-selection marker sacB, which originates from Bacillus subtilis. 20 When this gene is expressed via the integrated pUT-KB, it confers a sucrose-susceptibility phenotype, which enables positive selection with sucrose to detect loss of the vector.
Gene deletions in K. pneumoniae strain NVT1001 were constructed via in-frame deletion mutagenesis. 7 Briefly, two DNA fragments (1 kb in size)
that flanked the regions to be deleted were amplified by PCR using specific primer pairs. The two gel-purified PCR products, containing complementary ends, were then mixed and amplified via overlap PCR. 21, 22 The resulting PCR fragment (2 kb in size) was digested with restriction enzymes and then cloned into pUT-KB that had been similarly digested. For homologous recombination, each of the gene-deletion constructs in pUT-KB was transformed into E. coli S17-1 kpir 23 via electroporation and then mobilized into the K. pneumoniae strain NVT1001 via conjugation. Single crossover strains were selected from Brilliant green containing Inositol-NitrateDeoxycholate (BIND) plates supplemented with kanamycin (50 mg/L), as the growth of non-K. pneumoniae strains is effectively suppressed on BIND plates. 24 After the kanamycin-resistant transconjugants were selected, the insertions of the plasmids were verified via PCR using primer pairs that flanked the target genes. After incubation in 20 mL brain heart infusion (BHI) broth for 6 h at 37 C in the absence of kanamycin, the fully grown cultures were spread on to LB agar plates supplemented with 10% sucrose. After the double crossover occurred, the sucrose-resistant and kanamycinsusceptible colonies were selected, and the gene deletions were confirmed via PCR.
Site-directed mutagenesis
DNA fragments of the entire gyrA and parC sequences along with their flanking regions were amplified from K. pneumoniae strain NVT1001 using PCR with specific primer pairs and then cloned into the plasmid pUT-KB. The QuikChange site-directed mutagenesis kit (Stratagene) was used to generate mutations in the gyrA and parC genes in the plasmid using the methods described by the manufacturer. For homologous recombination, plasmids containing mutations in the gyrA or parC gene were transformed into E. coli S17-1 kpir 23 via electroporation and mobilized into K. pneumoniae strain NVT1001 via conjugation. Single crossover strains were selected from BIND plates supplemented with kanamycin (50 mg/L), as the growth of non-K. pneumoniae contaminants is suppressed on BIND plates. 24 After the kanamycin-resistant transconjugants were selected, the insertion of plasmids was verified via PCR. After incubation in 20 mL BHI broth for 6 h at 37 C in the absence of kanamycin, the fully grown cultures were spread on to LB agar plates supplemented with 10% sucrose. After the double crossover occurred, the sucrose-resistant and kanamycin-susceptible colonies were selected, and the gene mutations were confirmed via PCR.
Construction of revertants
The allelic-exchange method was used to restore the WT gene in the K. pneumoniae NVT1001 mutants with constructed chromosomemediated resistance mechanisms, as described by Tsai et al. 19 Briefly, a DNA fragment of the entire WT gene sequence along with flanking regions was amplified from K. pneumoniae NVT1001 using PCR with specific primers. The resulting PCR fragment was digested and then cloned into pUT-KB. For homologous recombination, this plasmid was transformed into E. coli S17-1 kpir 23 via electroporation and mobilized into the K. pneumoniae NVT1001 mutant via conjugation. Single crossover strains were selected from BIND plates supplemented with kanamycin (50 mg/L), as the growth of non-K. pneumoniae strains is effectively suppressed on the BIND plates. 24 After the kanamycin-resistant transconjugants were selected, the insertion of the plasmid was verified via PCR. After incubation in 20 mL BHI broth for 6 h at 37 C in the absence of kanamycin, the fully grown cultures were spread on to LB agar plates supplemented with 10% sucrose. After the double crossover occurred, the sucrose-resistant and kanamycin-susceptible colonies were selected, and the restoration of the WT gene was confirmed via DNA sequencing.
Plasmid construction and transformation
DNA fragments of the resistance genes along with their flanking regions were amplified from clinical plasmids via PCR with specific primer pairs.
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The resulting PCR fragments were digested and then cloned into the plasmid pACYC177 or pACYC184. The resulting plasmids were then transformed into K. pneumoniae strain NVT1001 via electroporation. The recombinant bacteria were plated on to LB agar plates containing kanamycin (50 mg/L) or chloramphenicol (50 mg/L), and the presence of the cloned gene was confirmed via PCR and DNA sequencing.
Antimicrobial susceptibility testing
The MICs of antibiotics were determined using the Etest (Biodisk AB, Sweden) or the MIC test strip (Liofilchem, Italy), according to the manufacturer's instructions. The MIC values, which fall between standard 2-fold dilutions, were rounded up to the next higher 2-fold value. The MICs of ceftazidime and cefotaxime against K. pneumoniae NVT1001 harbouring the pACYC177 plasmid with bla OXA-48 were further determined using a broth microdilution test according to the recommendations of the CLSI, 25 and the results were interpreted according to the breakpoints established by the CLSI in 2017. 25 Meanwhile, due to the lack of CLSI breakpoints in 2016 and 2017, the results for cefalotin were interpreted according to the breakpoints established by the CLSI in 2015, 26 and the results for moxifloxacin were interpreted according to the breakpoints established by the EUCAST in 2017. 27 
Mouse infection model
Pathogen-free 6-8-week-old male BALB/c mice were obtained from the National Laboratory Animal Center (Taiwan) and maintained in the pathogen-free vivarium of the Laboratory Animal Center of National Defense Medical Center (Taiwan). K. pneumoniae NVT1001 harbouring the pACYC177 plasmid with bla OXA-48 was cultured overnight at 37 C in BHI broth and then diluted (1:100) in fresh BHI broth. The culture was incubated until the mid-exponential growth phase, and the cells were then washed once, resuspended in 0.85% sterile saline, and adjusted to the desired concentrations according to the OD 600 value. The concentrations were verified by plating the cells to determine viable counts. Six mice from each group were then injected intraperitoneally with 0.1 mL of the cell suspension containing twice the LD 90-100 ; this inoculum of 4%10 3 cfu/mouse was known to be 100% lethal within 7 days (data not shown). Meanwhile, antibiotic doses were prepared in 0.85% sterile saline. At 1 h post-inoculation, antibiotic or 0.85% sterile saline alone was administered as a single subcutaneous injection with a volume of 0.3 mL per dose. The mice were then monitored daily for 7 days to measure survival. The ED 50 was defined as the single dose giving protection to 50% of the test mice.
Results
Porin loss and efflux-pump overexpression in antibiotic resistance
The MICs of antibiotics against chromosome-mediated resistance mechanisms, namely, OmpK35/36 loss and AcrAB-TolC overexpression (DramR), are shown in Table 2 . These results demonstrate that OmpK35/36 loss is related to increased resistance to b-lactams, folate pathway inhibitors, fosfomycins and nitrofurans, whereas AcrAB-TolC overexpression (DramR) is associated with increased resistance to b-lactams, quinolones, tetracyclines, folate pathway inhibitors, phenicols and nitrofurans. The two resistance mechanisms alone or in combination had no significant (4-fold) effects on the MICs of imipenem, aminoglycosides or polymyxins. The results shown above were further validated by testing the antimicrobial susceptibility of the revertant strains, and similar results were found when comparing the MIC for the WT strain NVT1001 or its mutant to the MIC for the revertant with the same genotype (Table S4) . 
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Antibiotics listed indicate a significant (4-fold) difference in the MICs for the NVT1001 strain and its genetically engineered strains in this study.
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b-Lactams
The MICs of b-lactams against associated resistance mechanisms are shown in Tables 3 and 4 . In particular, the MICs for organisms with ESBLs and AmpC b-lactamases are shown in Table 3 , while those for carbapenemases are shown in Table 4 . The production of ESBLs when tested alone showed no significant (4-fold) effects on Tsai et al. the MIC of piperacillin/tazobactam, cefoxitin, imipenem or doripenem, and the production of AmpC b-lactamases when tested alone showed no significant (4-fold) effects on the MIC of imipenem (Table 3) . With or without ESBLs or AmpC b-lactamases, the strains with AcrAB-TolC overexpression (DramR) all showed no significant (4-fold) effects on the MIC of imipenem or doripenem ( Table 3 ). The production of KPC-2 or KPC-3 alone could confer intermediate resistance to cefoxitin as well as resistance to the other tested b-lactams (Table 4 ). In addition, with or without OmpK35/36 loss and/or AcrAB-TolC overexpression (DramR), the IMP-8, NDM-1, VIM-1 and OXA-48 strains were susceptible to aztreonam (Table 4) .
Quinolones
The MICs of quinolones against chromosome-mediated resistance mechanisms are shown in Table 5 . Strains with a single mutation at GyrA (S83I, S83L, S83F, S83Y or D87N) or with AcrABTolC overexpression (DramR) showed significant (4-fold) increases in the MICs of all quinolones tested (Table 5 ). In contrast, the single mutation at ParC (S80I) showed no significant (4-fold) effects on the MIC of any of the quinolones tested, whereas significant (4-fold) increases in the MICs of quinolones were observed for the S83I, S83L, S83F, S83Y, S83I/D87N, S83L/D87N, S83F/D87N, S83Y/D87N and DramR/S83I mutants ( Table 5 ). The results shown above were further validated by testing the antimicrobial susceptibility of the revertant strains, and similar results were found when comparing the MIC for the WT strain NVT1001 or its mutant to the MIC for the revertant with the same genotype (Table S5 ). The MICs of quinolones against plasmid-mediated resistance mechanisms with or without combination with chromosomemediated resistance mechanisms are shown in Table 6 . In contrast to QnrB or QnrS, strains with AAC(6 0 )-Ib-cr exhibited a significant (4-fold) increase in the MIC of only ciprofloxacin or norfloxacin (Table 6 ). Even without plasmid-mediated resistance mechanisms, strains with the GyrA (S83I) mutation and AcrAB-TolC overexpression (DramR) could resist all tested quinolones (Table 6 ). Bold numbers indicate a significant (4-fold) difference in the MICs for the NVT1001 strain and its derived strains, while no significant (4-fold) differences in the MICs for the NVT1001 with or without plasmid pACYC177 alone (data not shown).
b Carbapenemase on the low-copy-number plasmid pACYC177 is shown, and the plasmid was transferred into K. pneumoniae NVT1001 and its mutants. TZB, tazobactam with a fixed concentration of 4 mg/L; CLA, clavulanic acid with a fixed concentration of 2 mg/L. c WT, NVT1001; D35, DompK35 mutant; D36, DompK36 mutant; D35/36, DompK35/36 mutant; DramR, DramR mutant; DramRD35, DramRDompK35 mutant; DramRD36, DramRDompK36 mutant; DramRD35/36, DramRDompK35/36 mutant. Antibiotic testing and screening system
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Aminoglycosides
The MICs of aminoglycosides for each resistance mechanism are shown in Table 7 . Several different resistance profiles were found among the strains with different aminoglycoside-modifying enzymes, though all were susceptible to amikacin ( Table 7) . The production of 16S rRNA methylase, ArmA and RmtB was not associated with observable effects on the MIC of spectinomycin or streptomycin, whereas both conferred strong resistance to all other aminoglycosides tested (Table 7) .
Tetracyclines
The MICs of tetracyclines for various resistance mechanisms are shown in Table 8 . With or without AcrAB-TolC overexpression (DramR), the production of Tet(B), Tet(C), Tet(D), or Tet(M) showed no observable effects on the MIC of tigecycline (Table 8) . AcrABTolC overexpression (DramR) and Tet(A) production both conferred an 8-fold increase in the MIC of tigecycline, and a 32-fold increase was found when the two mechanisms were combined (Table 8) .
Folate pathway inhibitors
The MICs of folate pathway inhibitors against associated resistance mechanisms are shown in Table 9 . Strains with single resistance mechanisms were all susceptible (2/38 mg/L) to trimethoprim/ sulfamethoxazole, and strains with certain combinations of mechanisms became resistant to trimethoprim/sulfamethoxazole (Table 9 ). Strains with porin loss and/or Sul production all showed no significant (4-fold) effects on the MIC of trimethoprim, whereas most of the other strains with combined mechanisms Bold numbers indicate a significant (4-fold) difference in the MICs for the NVT1001 strain and its derived strains, while no significant (4-fold) differences in the MICs for the NVT1001 with or without plasmid pACYC177 alone (data not shown).
b Qnr protein or the aminoglycoside-modifying enzyme on the low-copy-number plasmid pACYC177 is shown, and the plasmid was transferred into K. pneumoniae NVT1001 and its mutants. c WT, NVT1001; S83I, S83I mutant; S83I/S80I, S83I/S80I mutant; S83I/D87N/S80I, S83I/D87N/S80I mutant; DramR, DramR mutant; DramR/S83I, DramR/S83I mutant; DramR/S83I/S80I, DramR/S83I/S80I mutant; DramR/S83I/D87N/S80I, DramR/S83I/D87N/S80I mutant.
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were associated with significant (4-fold) increases in the MICs of all folate pathway inhibitors tested (Table 9 ).
In vivo investigation
To demonstrate further that this system can also be used to test the efficacy of antibiotics in vivo, a mouse infection model was used. The ED 50 values of ceftazidime and cefotaxime were specifically determined using K. pneumoniae NVT1001 harbouring the pACYC177 plasmid with bla OXA-48 (Figure 1 ). The in vivo efficacy of ceftazidime was higher than that of cefotaxime, which had an estimated ED 50 of 30 mg/kg, whereas no mice survived treatment with 30 mg/kg cefotaxime (Figure 1) . The higher efficacy of ceftazidime was also observed in the in vitro MIC assays, in which the MICs of ceftazidime and cefotaxime were 0.5 and 2 mg/L, respectively, using the broth microdilution test.
Discussion
In this study, 193 genetically engineered strains with different resistance mechanisms were constructed from K. pneumoniae NVT1001, a fully susceptible clinical isolate, including 29 strains with chromosome-mediated resistance, 33 strains with plasmidmediated resistance and 131 strains with a combination of the two resistance mechanisms. Because the resistance mechanisms of these strains were constructed, all are known to be resistant to specific antibiotics. In addition, the plasmid-mediated resistance mechanisms were constructed using non-conjugative plasmids without transposons, so these mechanisms are not easy to spread.
These features suggest that using these strains is safer than using drug-resistant clinical isolates.
Also in contrast to clinical drug-resistant isolates, these genetically engineered strains have clear and simple antibiotic resistance mechanisms. In in vitro MIC assays, the resistance profiles of these strains were confirmed by testing the MICs against several wellknown antibiotics. Investigators can estimate the effectiveness of their antibiotics by comparing their MIC results to those of wellknown antibiotics. The MIC assay is usually the starting point for assessing antibiotics, and our results suggest that these strains were ready for testing antibiotic activities in vitro.
In vivo mouse infection models are commonly used to demonstrate the efficacy of antibiotics in protecting against lethal infection. [28] [29] [30] Using a clinical K. pneumoniae isolate producing the carbapenemase OXA-48, a previous study found that the MIC of ceftazidime was 4-fold lower than that of cefotaxime and that the ED 50 of ceftazidime was lower than that of cefotaxime. 28 A similar result was obtained in the present study using K. pneumoniae NVT1001 harbouring the pACYC177 plasmid with bla OXA-48 . In contrast to many other clinical isolates, this genetically engineered strain can effectively infect BALB/c mice without weakening their immune system, and the LD 100 is 4%10 3 cfu in the mouse infection model as its parental strain NVT1001 (data not shown). Obtained without changing the immune system of mice, the in vivo results should be closer to the true antibiotic efficacy during clinical use. The results thus suggest that these genetically engineered strains are adequate for testing antibiotic activities in vivo.
For the development of antibiotics in the face of multidrug resistance, in vitro selection and earlier evaluation are important steps before in vivo studies and further clinical evaluation. In contrast to the use of clinical isolates, the use of the platform technology described here to evaluate antibiotics may elucidate the exact a Bold numbers indicate a significant (4-fold) difference in the MICs for the NVT1001 strain and its derived strains, while no significant (4-fold) differences in the MICs for the NVT1001 with or without plasmid pACYC177 alone (data not shown). b tet resistance gene on the low-copy-number plasmid pACYC177 is shown, and the plasmid was transferred into K. pneumoniae NVT1001.
Antibiotic testing and screening system JAC reason for and the level of resistance both in vitro and in vivo. This information may in turn help in estimation of the antibiotic efficacy and the potential resistance to antibiotics. The modification of antibiotics' chemical structure and discontinuities in development can lower the costs associated with the development process.
Furthermore, the global prevalence and distribution of antibiotic resistance genes are already available from various studies and monitoring groups. [31] [32] [33] [34] [35] [36] In combination with these data, the data obtained from this platform technology may help in the estimation of the rates of resistance to newly developed drugs across regions. Bold numbers indicate a significant ( 4-fold) difference in the MICs for the NVT1001 strain and its derived strains, while no significant (4-fold) differences in the MICs for the NVT1001 with or without plasmid pACYC177 alone (data not shown). Tsai et al.
Additionally, antibiotics should be used more carefully in regions where specific resistance mechanisms are epidemic.
The set of resistant strains included in this platform technology can be expanded. Specifically, through genetic construction, other resistance mechanisms or different combinations of mechanisms can also be constructed in the same parental strain, including newly identified mechanisms. Given that the genetic background of several important bacterial pathogens with high resistance rates is quite different from that of K. pneumoniae, specific resistance genes can be found in these pathogens. 37, 38 For example, the overexpression of the AdeABC efflux pump can confer antibiotic resistance in A. baumannii, whereas this efflux pump does not exist in K. pneumoniae. 37 To evaluate completely the activities of antibiotics, these specific resistance mechanisms should also be constructed in their original pathogens; in fact, several of them have been successfully constructed by our group (data not shown).
In conclusion, various chromosomal and plasmid resistance mechanisms were constructed in this study, and particularly mechanisms conferring resistance to b-lactams, quinolones, aminoglycosides, tetracyclines or folate pathway inhibitors. Our results demonstrate that this platform technology can be used to evaluate efficiently and effectively the antibiotics targeting specific resistance mechanisms both in vitro and in vivo. The system can also be used to screen new antibiotics against MDR bacteria.
